For patients with terminal cancer, chemotherapy does not improve quality of life
the ONA take:
Chemotherapy administered to patients with cancer who are near death does not improve quality of life and may even reduce quality of life in those who have good performance status, a recent study published in JAMA Oncology has shown.
For the study, researchers evaluated 312 patients with terminal cancer who were estimated to live no more than 6 months. The majority were receiving chemotherapy. Results showed that patients with a poor performance status who received chemotherapy achieved no improvement in quality of life during their final week prior to death.
Moreover, researchers found that in those with a good performance status, treatment worsened their quality of life compared with patients with a good performance status who were not receiving treatment.
Current American Society of Clinical Oncology (ASCO) guidelines contend that patients with terminal cancer and a good performance status are the most likely to benefit from chemotherapy, but these findings suggest that chemotherapy given to patients at the end of life may be wasteful, unnecessary, and potentially harmful.
Chemotherapy administered to patients with cancer who are near death does not improve quality of life.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Depression Predictive of Poor Survival Outcomes in Head and Neck Cancer
- Nearly One Third of Veterans Report Current Tobacco Use
- Priority Review of New Drug Application Granted to Apalutamide for CRPC
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|